Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eton Pharmaceuticals, Inc. - Common Stock (NQ:ETON)

47.15 -3.57 (-7.04%)
Delayed Quote Updated: 4:00 PM EST, Nov 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eton Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Eton Pharma (ETON) Q3 2026 Earnings Call Transcript ↗
Rare disease specialist posts record margins and raises outlook. 
Via The Motley Fool
Topics Earnings
News headline image
Eton Pharmaceuticals Q3 Earnings Call Highlights ↗
Eton Pharmaceuticals (NASDAQ:ETON) reported third-quarter revenue of $57.9 million, up 158% from a year earlier, and raised its full-year outlook after a full quarter of sales from HEMANGEOL and growth... 
Via MarketBeat
Topics Earnings
Eton Pharmaceuticals (NASDAQ:ETON) Surges on Q3 Beat and Raised Guidance ↗
Via Chartmill
After-Hours Market Movers for Nov. 5, 2026: Gainers and Losers ↗
Via Chartmill
ETON PHARMACEUTICALS INC (NASDAQ:ETON): High Growth Momentum Meets Breakout Setup ↗
Via Chartmill
Eton Pharmaceuticals (NASDAQ:ETON): High Growth Momentum Meets a Breakout Setup ↗
Via Chartmill
Eton Pharmaceuticals (NASDAQ:ETON) Soars on Q1 Beat, Raises Full-Year Guidance ↗
Via Chartmill
News headline image
Eton Pharmaceuticals Reports Third Quarter 2026 Financial Results
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals Announces Preliminary ET-700 Pilot Study Results Evaluating Copper Absorption Inhibition and Gastrointestinal Tolerability
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals Announces Licensing and Initiation of ET-900 Program Evaluating Mecasermin/IGF-1 for Treatment of Infantile and Epileptic Spasms
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals to Report Third Quarter 2026 Financial Results on Thursday, November 5, 2026
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazepam) Buccal Film
From Eton Pharmaceuticals; Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
Eton Pharmaceuticals Announces U.S. Commercial Availability of IMPAVIDO® (miltefosine) Capsules
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals to Participate at 2026 Wells Fargo Healthcare Conference
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals (ETON) Q2 2026 Earnings Call Transcript ↗
Revenue surged 99% year-over-year on HEMANGEOL relaunch and rare disease portfolio growth. 
Via The Motley Fool
Topics Earnings
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗
Via Chartmill
News headline image
Why Eton Pharmaceuticals Is Top of the Class Today ↗
Eton's cure for an expensive valuation: a 99% sales growth rate. 
Via The Motley Fool
Keep an eye on the top gainers and losers in Friday's session. ↗
Via Chartmill
Friday's session: gap up and gap down stocks ↗
Via Chartmill
Discover the top movers in Friday's pre-market session. ↗
Via Chartmill
News headline image
Eton Pharmaceuticals Q2 Earnings Call Highlights ↗
Eton Pharmaceuticals (NASDAQ:ETON) reported second-quarter revenue nearly doubled from a year earlier, driven by the relaunch of HEMANGEOL and growth across its pediatric endocrinology and rare-disease... 
Via MarketBeat
Topics Earnings
News headline image
Eton Pharmaceuticals Q2 2026 Earnings Call: Complete Transcript ↗
Eton Pharmaceuticals (NASDAQ:ETON) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. Benzinga APIs provide... 
Via Benzinga
Topics Earnings
Stay updated with the stocks that are on the move in today's after-hours session. ↗
Via Chartmill
News headline image
Eton Pharmaceuticals Reports Second Quarter 2026 Financial Results
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals Expands Infantile Hemangioma Franchise with Acquisition of U.S. Rights to Late-Stage Product Candidate ASN-001
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals to Report Second Quarter 2026 Financial Results on Thursday, August 13, 2026
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals Announces Submission of Prior Approval Supplement to Expand Indication of KHINDIVI® (hydrocortisone) Oral Solution
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals Expands Rare Disease Portfolio Through Agreement for U.S. Commercialization Rights to IMPAVIDO® (miltefosine)
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton (ETON) Q1 2026 Earnings Call Transcript ↗
Eton (ETON) Q1 2026 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Eton Pharmaceuticals Q1 Earnings Call Highlights ↗
Eton Pharmaceuticals (NASDAQ:ETON) raised its 2026 revenue outlook after reporting record first-quarter product sales and highlighting early progress from two recent product launches, DESMODA and... 
Via MarketBeat
Topics Earnings
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.